Breast Cancer Action is one of very few health organizations that refuses to take funding from pharmaceutical companies. Because of our strict conflict of interest policy, we can be an unbiased and independent watchdog for your health. We always evaluate and report on developments in breast cancer treatment and screening from a patient-centered perspective. All year long, we’re monitoring developments and news in breast cancer treatment, screening, and diagnostics; here’s a quick update on some important breast cancer issues.
- In June a study published in the New England Journal of Medicine evaluated the efficacy of extending the treatment of letrozole from five to ten years for women with hormone positive breast cancer. On our blog, I discussed the trade-offs of ten years of aromatase inhibitors.
- A few weeks ago, new research also published in the New England Journal of Medicine showed that a large percentage of women with early-stage breast cancer who have been identified as having a high risk of recurrence can consider forgoing chemotherapy based on the biological makeup of their tumor. I discussed this new research with the San Francisco Chronicle and KQED.
- If you weren’t able to attend our recent webinar on the Lymphedema Treatment Act, you can watch it on our website here. Medicare and other insurance companies don’t currently cover the costs of lymphedema treatments, leaving patients who can’t afford them to suffer with this debilitating condition. We’re working with our partners at the National Lymphedema Network to change that.
- With October around the corner, you’re likely to hear “get screened” a lot. Don’t miss our patient-centered, evidence-based brochure, “Should I Get a Mammogram?” Understanding the Harms and Benefits of Routine Breast Cancer Screening.
If you have questions about any of these issues, you can get in touch with our Information & Resource Liaison, Zoe Christopher; she won’t give medical advice, but she can help you sort through information and options so you know what questions to ask and can make informed decisions about breast cancer treatment or screening. And if you’re not already, follow us on Facebook and Twitter to get daily updates on our work, as well as our unique analysis on breast cancer issues.